Table 2 Baseline characteristics of patients treated with bDMARDs
N | TNFi | ABA | TCZ | p |
|---|---|---|---|---|
806 | 352 | 204 | ||
Age (yr) | 62 (51–71) | 68 (60–76) | 63 (54–70) | < 0.001 |
 < 65/65–74/≥ 75 yr (%) | 56.6/28.4/15 | 34.9/32.4/32.7 | 56.9/28.9/14.2 | < 0.001 |
Gender (female) (%) | 79.9 | 85.5 | 81.4 | 0.077 |
Disease duration (yr) | 3 (0.8–9) | 7 (2–16) | 5 (1.3–12) | < 0.001 |
Stage (I + II) (%) | 74.1 | 56.3 | 65.7 | < 0.001 |
Bio-naïve (%) | 80.1 | 63.6 | 68.1 | < 0.001 |
MTX use (%) | 87.5 | 66.5 | 58.8 | < 0.001 |
MTX dose (mg/w) | 14 (10–16) | 12 (8–16) | 12 (8–16) | < 0.001 |
GC use (%) | 17.6 | 24.4 | 29.9 | < 0.001 |
 GC dose (mg/d) | 4.5 (2.5–6.3) | 4.5 (2.5–8) | 5 (2.5–7.8) | 0.672 |
CRP (mg/dL) | 0.8 (0.2–3) | 0.7 (0.1–2) | 2.3 (0.7–5.3) | < 0.001 |
ESR (mm/h) | 43 (20–73) | 44 (24–71) | 63 (40–85) | < 0.001 |
RF (IU/mL) | 52 (16–151) | 78 (25–199) | 72 (19–161) | 0.003 |
ACPA positive (%) | 72.5 | 76.1 | 71.6 | 0.274 |
TJC, 0–28 | 7 (4–12) | 6 (3–12) | 8 (4–13) | 0.008 |
SJC, 0–28 | 6 (3–10) | 6 (2–9) | 7 (4–11) | 0.001 |
PGA, 0–100 (mm) | 52 (35–71) | 50 (33–71) | 55 (38–75) | 0.168 |
EGA, 0–100 (mm) | 45 (30–60) | 40 (25–52) | 43 (31–59) | 0.002 |
CDAI | 24 (16–32) | 22 (15–31) | 26 (18–35) | 0.001 |
HAQ-DI | 1.1 (0.5–1.9) | 1.4 (0.6–2.1) | 1.4 (0.8–2.1) | 0.004 |
Pre-existing lung disease (%) | 22.5 | 39.8 | 25.5 | < 0.001 |